ICOS' MS Drug In Clinical Trials Soon?
Clinical trials for ICOS Corporation's monoclonal antibody treatment for multiple sclerosis are expected to start within the next couple of weeks, according to executive vice president and scientific director of the company Chris Henney.
23f2G is a humanized antibody targeting leukointegrin, a cell adhesion receptor found on the surface of leukocytes with a central role in the trafficking of the cells from the circulation into the extravascular spaces. In effect, the antibody prevents the cells from attaching to the blood vessel wall.
ICOS filed an Investigational New Drug application in the USA to begin clinical trials in December 1993, and the delay to date has resulted from the Food and Drug Administration requesting more data on safety and efficacy. In the interim, ICOS has put into place its clinical and manufacturing capabilities and established clinical sites for Phase I trials.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze